The article’s main point is that discovery-stage in vivo studies are run with very little drug, and that makes formulation risky. If the formulation fails, a study can give negative or ambiguous results that lead to erroneous conclusions, and research programs may be terminated based on flawed data.
The article describes the limits formulators work under at this stage. Purity may not be optimal, log P and pKa are usually not measured, solid-state properties such as crystallinity and polymorphism are unknown, and a small drug supply limits solubility testing. In addition, stability is often not fully evaluated, and quick, non-validated HPLC methods add inaccuracy. Even so, good formulation work can manage that risk and make it possible to tell lead compounds apart. The ideal is a “universal formulation” that works across a structurally similar lead series, because it makes their in vivo results directly comparable.
The article also points to an access gap. Large pharma has in-house teams for this work, while academics, biotechs, and startups have limited access. Many pharmacology CROs offer standardized, poorly characterized formulations, sometimes with DMA or NMP, which may be unacceptable in some animal models.
The recommended approach is to start from molecular structure, calculated log P/pKa, and any available data, then run microscale solubility screens of co-solvents, surfactants, lipids, and cyclodextrins. For crystalline compounds, the authors recommend particle size reduction, using small-volume media mills that make nanocrystal suspensions under 1 mL. These methods are often combined. Careful excipient choice can raise solubility by orders of magnitude, for example from 1 to 100 μg/mL, with better PK. Ascendia’s scientists use a decision tree to guide the design, and formulations should cover the PO, IV, IN, IM, and SC routes.
The article ends by saying that this early work supports later clinical dosage forms and the target product profile, and that non-obvious biopharmaceutics findings can create IP beyond composition-of-matter patents.
Early in vivo studies decide which compounds move forward. A poor formulation can cause low or variable exposure, and that can make a promising compound look like it failed. The result can be a wrong lead selection or a program that gets stopped on flawed data.
Formulators usually have milligram amounts of drug, unoptimized purity, and no measured log P, pKa or solid-state data. They also have limited stability data and non-validated analytical methods. All of this makes solubility and stability results less reliable.
It is a single vehicle that works for a whole series of structurally similar lead compounds. Because every compound is dosed the same way, differences in PK and efficacy can be traced to the molecule rather than to the formulation.
Common methods are microscale screening of co-solvents, surfactants, lipids, and cyclodextrins, and nanocrystal suspensions for crystalline compounds. These are often combined. Well-chosen excipients can raise solubility by about 100-fold, for example from 1 to 100 μg/mL.
These solvents may be unacceptable in some animal models. Using them in standardized CRO vehicles can affect tolerability and make the study data harder to interpret.
They should look for preformulation, formulation, and biopharmaceutics expertise; methods that work with very small amounts of drug; and the ability to formulate for oral, IV, intranasal, IM, and subcutaneous routes.
It shapes the target product profile and lays the groundwork for clinical dosage forms. Non-obvious biopharmaceutics findings can also be patented, which adds IP beyond the basic composition-of-matter patent.